Nanoparticle formulation of ormeloxifene for pancreatic cancer

Sheema Khan, Neeraj Chauhan, Murali Yallapu, Mara C. Ebeling, Swathi Balakrishna, Robert T. Ellis, Paul A. Thompson, Pavan Balabathula, Stephen W. Behrman, Nadeem Zafar, Man M. Singh, Fathi T. Halaweish, Meena Jaggi, Subhash Chauhan

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Pancreatic cancer is the fourth most prevalent cancer with about an 85% mortality rate; thus, an utmost need exists to discover new therapeutic modalities that would enhance therapy outcomes of this disease with minimal or no side effects. Ormeloxifene (ORM), a synthetic molecule, has exhibited potent anti-cancer effects through inhibition of important oncogenic and proliferation signaling pathways. However, the anti-cancer efficacy of ORM can be further improved by developing its nanoformulation, which will also offer tumor specific targeted delivery. Therefore, we have developed a novel ORM encapsulated poly(lactic- co-glycolic acid) nanoparticle (NP) formulation (PLGA-ORM NP). This formulation was characterized for particle size, chemical composition, and drug loading efficiency, using various physico-chemical methods (TEM, FT-IR, DSC, TGA, and HPLC). Because of its facile composition, this novel formulation is compatible with antibody/aptamer conjugation to achieve tumor specific targeting. The particle size analysis of this PLGA-ORM formulation (~100nm) indicates that this formulation can preferentially reach and accumulate in tumors by the Enhanced Permeability and Retention (EPR) effect. Cellular uptake and internalization studies demonstrate that PLGA-ORM NPs escape lysosomal degradation, providing efficient endosomal release to cytosol. PLGA-ORM NPs showed remarkable anti-cancer potential in various pancreatic cancer cells (HPAF-II, AsPC-1, BxPC-3, Panc-1, and MiaPaca) and a BxPC-3 xenograft mice model resulting in increased animal survival. PLGA-ORM NPs suppressed pancreatic tumor growth via suppression of Akt phosphorylation and expression of MUC1, HER2, PCNA, CK19 and CD31. This study suggests that the PLGA-ORM formulation is highly efficient for the inhibition of pancreatic tumor growth and thus can be valuable for the treatment of pancreatic cancer in the future.

Original languageEnglish (US)
Pages (from-to)731-743
Number of pages13
JournalBiomaterials
Volume53
DOIs
StatePublished - Jun 1 2015

Fingerprint

Pancreatic Neoplasms
Nanoparticles
Tumors
Neoplasms
Phosphorylation
Particle Size
Chemical analysis
Antibodies
Particle size analysis
Animals
Particle size
Cells
ormeloxifene
Transmission electron microscopy
Degradation
Proliferating Cell Nuclear Antigen
Molecules
Acids
Growth
polylactic acid-polyglycolic acid copolymer

All Science Journal Classification (ASJC) codes

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Nanoparticle formulation of ormeloxifene for pancreatic cancer. / Khan, Sheema; Chauhan, Neeraj; Yallapu, Murali; Ebeling, Mara C.; Balakrishna, Swathi; Ellis, Robert T.; Thompson, Paul A.; Balabathula, Pavan; Behrman, Stephen W.; Zafar, Nadeem; Singh, Man M.; Halaweish, Fathi T.; Jaggi, Meena; Chauhan, Subhash.

In: Biomaterials, Vol. 53, 01.06.2015, p. 731-743.

Research output: Contribution to journalArticle

Khan, S, Chauhan, N, Yallapu, M, Ebeling, MC, Balakrishna, S, Ellis, RT, Thompson, PA, Balabathula, P, Behrman, SW, Zafar, N, Singh, MM, Halaweish, FT, Jaggi, M & Chauhan, S 2015, 'Nanoparticle formulation of ormeloxifene for pancreatic cancer', Biomaterials, vol. 53, pp. 731-743. https://doi.org/10.1016/j.biomaterials.2015.02.082
Khan, Sheema ; Chauhan, Neeraj ; Yallapu, Murali ; Ebeling, Mara C. ; Balakrishna, Swathi ; Ellis, Robert T. ; Thompson, Paul A. ; Balabathula, Pavan ; Behrman, Stephen W. ; Zafar, Nadeem ; Singh, Man M. ; Halaweish, Fathi T. ; Jaggi, Meena ; Chauhan, Subhash. / Nanoparticle formulation of ormeloxifene for pancreatic cancer. In: Biomaterials. 2015 ; Vol. 53. pp. 731-743.
@article{0386ddb0ef8c47688cd823cdec73cded,
title = "Nanoparticle formulation of ormeloxifene for pancreatic cancer",
abstract = "Pancreatic cancer is the fourth most prevalent cancer with about an 85{\%} mortality rate; thus, an utmost need exists to discover new therapeutic modalities that would enhance therapy outcomes of this disease with minimal or no side effects. Ormeloxifene (ORM), a synthetic molecule, has exhibited potent anti-cancer effects through inhibition of important oncogenic and proliferation signaling pathways. However, the anti-cancer efficacy of ORM can be further improved by developing its nanoformulation, which will also offer tumor specific targeted delivery. Therefore, we have developed a novel ORM encapsulated poly(lactic- co-glycolic acid) nanoparticle (NP) formulation (PLGA-ORM NP). This formulation was characterized for particle size, chemical composition, and drug loading efficiency, using various physico-chemical methods (TEM, FT-IR, DSC, TGA, and HPLC). Because of its facile composition, this novel formulation is compatible with antibody/aptamer conjugation to achieve tumor specific targeting. The particle size analysis of this PLGA-ORM formulation (~100nm) indicates that this formulation can preferentially reach and accumulate in tumors by the Enhanced Permeability and Retention (EPR) effect. Cellular uptake and internalization studies demonstrate that PLGA-ORM NPs escape lysosomal degradation, providing efficient endosomal release to cytosol. PLGA-ORM NPs showed remarkable anti-cancer potential in various pancreatic cancer cells (HPAF-II, AsPC-1, BxPC-3, Panc-1, and MiaPaca) and a BxPC-3 xenograft mice model resulting in increased animal survival. PLGA-ORM NPs suppressed pancreatic tumor growth via suppression of Akt phosphorylation and expression of MUC1, HER2, PCNA, CK19 and CD31. This study suggests that the PLGA-ORM formulation is highly efficient for the inhibition of pancreatic tumor growth and thus can be valuable for the treatment of pancreatic cancer in the future.",
author = "Sheema Khan and Neeraj Chauhan and Murali Yallapu and Ebeling, {Mara C.} and Swathi Balakrishna and Ellis, {Robert T.} and Thompson, {Paul A.} and Pavan Balabathula and Behrman, {Stephen W.} and Nadeem Zafar and Singh, {Man M.} and Halaweish, {Fathi T.} and Meena Jaggi and Subhash Chauhan",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.biomaterials.2015.02.082",
language = "English (US)",
volume = "53",
pages = "731--743",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Nanoparticle formulation of ormeloxifene for pancreatic cancer

AU - Khan, Sheema

AU - Chauhan, Neeraj

AU - Yallapu, Murali

AU - Ebeling, Mara C.

AU - Balakrishna, Swathi

AU - Ellis, Robert T.

AU - Thompson, Paul A.

AU - Balabathula, Pavan

AU - Behrman, Stephen W.

AU - Zafar, Nadeem

AU - Singh, Man M.

AU - Halaweish, Fathi T.

AU - Jaggi, Meena

AU - Chauhan, Subhash

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Pancreatic cancer is the fourth most prevalent cancer with about an 85% mortality rate; thus, an utmost need exists to discover new therapeutic modalities that would enhance therapy outcomes of this disease with minimal or no side effects. Ormeloxifene (ORM), a synthetic molecule, has exhibited potent anti-cancer effects through inhibition of important oncogenic and proliferation signaling pathways. However, the anti-cancer efficacy of ORM can be further improved by developing its nanoformulation, which will also offer tumor specific targeted delivery. Therefore, we have developed a novel ORM encapsulated poly(lactic- co-glycolic acid) nanoparticle (NP) formulation (PLGA-ORM NP). This formulation was characterized for particle size, chemical composition, and drug loading efficiency, using various physico-chemical methods (TEM, FT-IR, DSC, TGA, and HPLC). Because of its facile composition, this novel formulation is compatible with antibody/aptamer conjugation to achieve tumor specific targeting. The particle size analysis of this PLGA-ORM formulation (~100nm) indicates that this formulation can preferentially reach and accumulate in tumors by the Enhanced Permeability and Retention (EPR) effect. Cellular uptake and internalization studies demonstrate that PLGA-ORM NPs escape lysosomal degradation, providing efficient endosomal release to cytosol. PLGA-ORM NPs showed remarkable anti-cancer potential in various pancreatic cancer cells (HPAF-II, AsPC-1, BxPC-3, Panc-1, and MiaPaca) and a BxPC-3 xenograft mice model resulting in increased animal survival. PLGA-ORM NPs suppressed pancreatic tumor growth via suppression of Akt phosphorylation and expression of MUC1, HER2, PCNA, CK19 and CD31. This study suggests that the PLGA-ORM formulation is highly efficient for the inhibition of pancreatic tumor growth and thus can be valuable for the treatment of pancreatic cancer in the future.

AB - Pancreatic cancer is the fourth most prevalent cancer with about an 85% mortality rate; thus, an utmost need exists to discover new therapeutic modalities that would enhance therapy outcomes of this disease with minimal or no side effects. Ormeloxifene (ORM), a synthetic molecule, has exhibited potent anti-cancer effects through inhibition of important oncogenic and proliferation signaling pathways. However, the anti-cancer efficacy of ORM can be further improved by developing its nanoformulation, which will also offer tumor specific targeted delivery. Therefore, we have developed a novel ORM encapsulated poly(lactic- co-glycolic acid) nanoparticle (NP) formulation (PLGA-ORM NP). This formulation was characterized for particle size, chemical composition, and drug loading efficiency, using various physico-chemical methods (TEM, FT-IR, DSC, TGA, and HPLC). Because of its facile composition, this novel formulation is compatible with antibody/aptamer conjugation to achieve tumor specific targeting. The particle size analysis of this PLGA-ORM formulation (~100nm) indicates that this formulation can preferentially reach and accumulate in tumors by the Enhanced Permeability and Retention (EPR) effect. Cellular uptake and internalization studies demonstrate that PLGA-ORM NPs escape lysosomal degradation, providing efficient endosomal release to cytosol. PLGA-ORM NPs showed remarkable anti-cancer potential in various pancreatic cancer cells (HPAF-II, AsPC-1, BxPC-3, Panc-1, and MiaPaca) and a BxPC-3 xenograft mice model resulting in increased animal survival. PLGA-ORM NPs suppressed pancreatic tumor growth via suppression of Akt phosphorylation and expression of MUC1, HER2, PCNA, CK19 and CD31. This study suggests that the PLGA-ORM formulation is highly efficient for the inhibition of pancreatic tumor growth and thus can be valuable for the treatment of pancreatic cancer in the future.

UR - http://www.scopus.com/inward/record.url?scp=84927931657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927931657&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2015.02.082

DO - 10.1016/j.biomaterials.2015.02.082

M3 - Article

VL - 53

SP - 731

EP - 743

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -